Bristol-Myers Squibb Company and Calithera Biosciences , Inc. , a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma . CB-839 is an orally administered glutaminase inhibitor currently in Phase 1/2 clinical studies.
Category: Healthcare Industry
Shionogi And Purdue Pharma L.P. Establish Alliance For Joint U.S. Commercialization Of Naldemedine
OSAKA, Japan & STAMFORD, Conn.– — Shionogi & Co., Ltd. , a drug-discovery based pharmaceutical company dedicated to developing medicines that protect the health and well-being of patients, and its wholly-owned U.S. subsidiary, Shionogi Inc. , and Purdue Pharma L.P. , a privately-held pharmaceutical company founded by physicians over 60 years ago, distinguished by its pioneering research, products and medical programs directed toward alleviating pain, today announced the establishment of an alliance for the joint U.S. launch and commercialization of SymproicA .
Merck Wins Record $2.5 Billion Patent Verdict Against Gilead
Gilead Sciences Inc. was told by a federal jury to pay $2.54 billion to Merck & Co. for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C — the biggest patent-infringement verdict in U.S. history.
Oncolytics Biotech Inc. Announces 2016 Year-End Results
“Through this process, and with the help of our expanding senior team, we thoughtfully and deliberately put in place a plan that initially contemplates combinations with chemotherapy for late-stage clinical development, but will expand to include targeted immunotherapies over the longer term as we look to leverage the role of the immune system in patient treatment. In the coming months we will specifically define our first registration pathway.